リミニストリート、IT部門における「Company of the Year」を受賞

7つの部門で、業界リーダーとしての地位、社会貢献の取り組み、カスタマーサービス向上への飽くなき取り組みが評価

ラスベガス--(BUSINESS WIRE)--(ビジネスワイヤ) -- エンタープライズソフトウェア製品を対象としたサポートサービスの世界的プロバイダーであり、OracleおよびSAPソフトウェアの第三者保守サポートにおいて業界をリードするリミニストリート(Nasdaq:RMNI)は、2017年のGolden Bridge Awardsにおいて、ITサービスの分野における「Company of the Year」と「Customer Service Department of the Year」の金賞を含め、7つの賞を受賞したことを発表しました。リミニストリートはこのほかにも、「Corporate Social Responsibility Program of the Year」、「Fastest Growing Company of the Year」、「Customer Service Team of the Year」、「Brand Awareness Video」といった各賞も獲得しています。また、リミニストリートは、その卓越したパフォーマンスが3つ以上のカテゴリで評価され、Grand Trophyの受賞企業にも選出されました。この賞を受賞した企業はわずか5社のみとなっています。



Golden Bridge Awardsプログラムでは毎年、全世界の主要な業界すべてを対象に、組織のパフォーマンス、イノベーション、製品およびサービス、顧客満足度プログラムなどの観点からその功績を表彰しています。本年度は、2017年9月18日にサンフランシスコで、受賞者の発表がありました。

ソフトウェア保守サポート市場のリーダー、イノベーターとして確固たる地位を獲得

リミニストリートは創業から12年間にわたり、ベンダーの標準サポートプラグラムで一般に提供される内容を上回る、エンタープライズソフトウェア向けの革新的で高品質な保守サポートサービスを広範に提供することに注力してきました。リミニストリートのサービスをご利用いただければ、ベンダーの標準サポートにかかる年間保守料と比較して、コストを50%削減することが可能です。

今回の「Company of the Year」の受賞は、2016年における成長、拡大の実績をもとに評価されたもので、リミニストリートがソフトウェア保守サポートの市場におけるリーダーおよびイノベーターの地位にあることを裏付けるものとなっています。昨年の事業の拡大の一例としては、SAP HANA DatabaseおよびOracle ATG Web Commerceの保守サポートサービスを新たに開始したことや、大阪ソウルメルボルンストックホルムに事業所を開設してグローバル展開を加速したことなどが挙げられます。

また、リミニストリートは2016年会計年度通年での業績報告の結果から「Fastest Growing Company of the Year」の受賞企業にも選ばれており、さらに、今年のはじめには、2017 American Business AwardsSMにおいて、スティービーアワードの「Most Innovative Tech Company of the Year」も受賞しています。

この他にもリミニストリートは、「Corporate Social Responsibility Program of the Year」も受賞しています。これは、リミニストリートの従業員の職場や住まいのある世界各国のコミュニティで果たしている社会貢献が評価されたものです。2015年以降、リミニストリートは100%出資で設立したリミニストリート財団を通じ、数々の国で数十に上るチャリティ活動に貢献しています。また、従業員も、世界各国で様々なボランティア活動に従事してきました。

カスタマーサービスの分野で複数の賞を受賞

また、リミニストリートのグローバルサービスデリバリーのチームとグロ-バルSiebelサービスデリバリーのチームは、その提供するカスタマーサービスが常に高い品質を維持している点で再評価を得ることができました。この「Customer Service Department of the Year」金賞の受賞につながった活動において、グローバルサービスデリバリーのチームは、2016年に、全体的な顧客満足度の評価で5点満点中4.8のスコアを達成しています。加えて、緊急対応を要する優先度1(P1)のケースにおいて、初回応答に要する時間を平均5分未満に抑え、内容が非常に複雑なレベル3のケースを19,000件以上解決しています。

さらに、グロ-バルSiebelサービスデリバリーのチームは、応答性のきわめて高い高品質なサービスをグローバルレベルで顧客に提供している取り組みが評価され、「Customer Service Team of the Year」を受賞しています。この取り組みで、同チームは、社内で最も高い顧客満足度の評価(5点満点でほぼ満点に近い4.96)を得るとともに、重要度の高い問題の対応で平均5分未満の応答時間を達成しています。

このほかに、リミニストリートはそのマーケティング活動でも評価を受け、「Video – Brand Awareness」のカテゴリで金賞を受賞しています。

リミニストリートのCEO、Seth A. Ravinは次のように述べています。

「当社は12年前の創業以来、一貫してお客様の成功に主眼を置き、これをコアのミッションとして飽くことなく努力を重ねてきましたが、この取り組みが改めて評価され、「Company of the Year」などの賞を受賞できたことを大変誇りに思っています。今後もリミニストリートは、既存のIT投資の価値を最大化して、ビジネスの拡大を実現するさらなる力や競争上の優位性を得られるよう、お客様を支援してまいります」

Golden Bridge Awardsについて

Golden Bridge Awardsは、北米、欧州、中東、アフリカ、アジア太平洋、南米の主要なあらゆる業界の大企業、中小企業、新規スタートアップ企業を対象にその功績を業界、同業者のレベルで毎年讃える表彰プログラムです。優れた新製品およびサービス、最高レベルのイノベーション、マネージメントおよびチーム、ビジネスウーマンおよびプロフェッショナルウーマン、ケーススタディ、顧客満足度、PRおよびマーケティングキャンペーンの観点からグローバルな評価を行います。Golden Bridge Awardsの詳細については、www.goldenbridgeawards.comをご覧ください。

リミニストリートについて

リミニストリート(Nasdaq: RMNI)は、エンタープライズソフトウェア製品とサービスの世界的プロバイダーで、Oracle®およびSAP® ソフトウェアの第三者保守サポートにおいて業界をリードしています。2005年以来、多くの受賞歴を持つ革新的プログラムにより、エンタープライズソフトウェア向けサポートサービスのあり方を塗り替えてきました。これにより、IBM、Microsoft、Oracle、SAPおよびその他のエンタープライズソフトウェアを利用するライセンシーにかかる総サポート費用の最大90%を削減することを可能にしています。そしてお客様は、現行のソフトウェアリリースを、アップグレードなしに少なくとも15年間使い続けることが出来るようになります。多様な業界のグローバル企業、フォーチュン500企業、中規模企業、公共セクター組織を含む1,330社以上の顧客が、信頼できる第三者保守サポートプロバイダーとして、リミニストリートにサポートを委託しています。詳細はhttp://www.riministreet.comをご覧ください。またTwitter (@riministreet )、 FacebookLinkedInでリミニストリートをフォローしてください。 (C-RMNI)

将来見通しに関する記述

本プレスリリースには、過去に関する事実ではなく、1995年米国民事証券訴訟改革法のセーフハーバー規定に定義する将来見通しに関する記述が含まれています。通常、将来見通しに関する記述には、「かもしれない」、「はずだ」、「だろう」、「計画する」、「意図する」、「期待する」、「考える」、「推定する」、「予測する」、「可能性」、「思われる」、「求める」、「継続する」、「将来~だろう」、「期待する」、「見通し」などの単語や、その他類似の語句や表現が使用されます。これらの将来見通しに関する記述には、我々の業界や将来の事象をはじめ、予期される経営、本取引後に推定または期待されるリミニストリートの将来の業績や利益(予想される本取引後の所有権および現金と負債の残高、将来における機会、リミニストリートの有効市場に関する推定、顧客にとっての節約効果に関する予測などを含む)に関する記述が含まれます(ただしこれらには限定されない)。これらの記述は、さまざまな仮定および経営陣の現時点の期待に基づいており、実際の業績を予測するものではなく、過去に関する事実に基づく記述でもありません。これらの記述は、リミニストリートのビジネスに関連する多くのリスクおよび不確実性に左右されるものであり、実際の結果は大きく異なる可能性があります。これらのリスクおよび不確実性としては次のもの(ただしこれらには限定されない)が挙げられます。リミニストリートが活動するビジネス環境における変化(リミニストリートが活動する業界に影響を与えるインフレや金利、一般的な財務、経済、規制、および政治的な状況などを含む)。 不利な訴訟。好条件で既存債務を借り換えられないこと。税金、政府の法律、および規制の改正。競合製品と価格設定。増益管理の困難性。リミニストリートの経営陣メンバーの終任。本取引につき期待されているメリットを実現できないこと(GPIACとリミニストリートの業務統合の困難性を含む)。RMNIの普通株式の長期的な価値の不確実性。コスト削減および運用シナジーに関して期待された金額やタイミングを実現できないこと。GPIACとリミニストリートの四半期報告書(Form 10-Q)および証券取引委員会(「SEC」)に提出されるGPIACとリミニストリートのその他の文書により適宜更新される、2016年12月31日を末日とする年度に係るGPIACの年次報告書(Form 10-K)の「Risk Factors」という見出しの下に記述されている事項、またはGPIACがSECに提出する共同委任勧誘状/目論見書に記述されている事項。また、リミニストリートが現在重要でないと認識しまたは信じている追加のリスクが原因となり、実際の結果が将来見通しに関する記述の内容と異なることになる可能性もあります。さらに、将来見通しに関する記述には、本プレスリリースの発表時点でのリミニストリートの将来の事象に関する期待、計画、または予測、および考えが示されています。リミニストリートは、後発事象や今後の進展がリミニストリートの評価を変える原因になると予想しています。ただし、リミニストリートは、これらの将来見通しに関する記述を将来のある時点で更新することを選択する可能性がある一方で、そのような義務を明示的に否認いたします。これらの将来見通しに関する記述は、本プレスリリース発行日後の時点におけるリミニストリートの評価を表すものとして依拠されるべきではありません。

© 2017 Rimini Street, Inc. All rights reserved. Rimini Streetは、米国およびその他の国におけるリミニストリートの登録商標です。Rimini Street、Rimini Streetロゴ、およびその組み合わせ、その他TMの付いたマークは、リミニストリートの商標です。その他のすべての商標は、それぞれの所有者の財産権を構成するものであり、別段の記載がない限り、リミニストリートは、これらの商標保有者またはここに記載されているその他の企業と提携や協力関係にあるものでも、またそれらを支持しているものでもありません。

本記者発表文の公式バージョンはオリジナル言語版です。翻訳言語版は、読者の便宜を図る目的で提供されたものであり、法的効力を持ちません。翻訳言語版を資料としてご利用になる際には、法的効力を有する唯一のバージョンであるオリジナル言語版と照らし合わせて頂くようお願い致します。


Contacts

本件に関する報道関係のお問い合わせ先
船見厚宏
日本リミニストリート PR担当
rimini@wizbrains.com

NTT Communications Named a Leader in 2017 Gartner Magic Quadrant for Managed Hybrid Cloud Hosting, Asia/Pacific, for Third Year in a Row

TOKYO--(BUSINESS WIRE)--NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (TOKYO:9432) announced today that it was positioned in the Leaders quadrant of the "Magic Quadrant for Managed Hybrid Cloud Hosting, Asia/Pacific" report published by Gartner Inc. for the third consecutive year, based on ability to execute and completeness of vision.


Gartner defines managed hybrid cloud hosting (MHCH) as a standardized and productized offering that combines a cloud-enabled system infrastructure platform—consisting of a pool of compute, network and storage hardware—with cloud infrastructure framework software to facilitate self-service and rapid provisioning. According to Gartner, “Providers require a strong strategy to become a Leader in Asia. They need to invest in their products, geographic coverage and delivery capabilities to the extent that they can become strong regional players. To build their market positions, they must have the ability and willingness to invest for the future.”

"We're delighted to be recognized as a leader in Managed Hybrid Cloud Hosting market for the third year in a row," said Masaaki Moribayashi, Senior Vice President of Cloud Services at NTT Com. "As the cloud factory developing and operating cloud services for NTT Group, including Dimension Data, NTT Com will further enhance its cloud offerings and partnerships to support our enterprise clients engaging in new business opportunities.” 

NTT Com will continue to offer flexible and secure ICT by taking initiative in the managed hybrid ICT area. This initiative includes strengthening of our cloud offering through partnerships, expansion of global cloud delivery centers and further deployment of software-defined technologies connecting data centers, cloud and network services. On the management side, NTT Com will further enhance its managed service capabilities including our Cloud Management Platform (CMP), which visualizes clients’ entire hybrid ICT resources and support their digital transformation journey.

Magic Quadrant for Managed Hybrid Cloud Hosting, Asia/Pacific, To Chee Eng et al. 31 October 2017. The report can be viewed here.

Related Links

About NTT Communications Corporation
NTT Communications provides consultancy, architecture, security and cloud services to optimize the information and communications technology (ICT) environments of enterprises. These offerings are backed by the company’s worldwide infrastructure, including the leading global tier-1 IP network, the Arcstar Universal One™ VPN network reaching over 190 countries/regions, and over 140 secure data centers worldwide. NTT Communications’ solutions leverage the global resources of NTT Group companies including Dimension Data, NTT DOCOMO and NTT DATA.
www.ntt.com | Twitter@NTT Com | Facebook@NTT Com | LinkedIn@NTT Com

[Gartner Disclaimer]
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.


Contacts

For More Information
NTT Communications Corporation
Ms. Yuko Miyamoto / Ms. Aoi Funagoshi, +81 3 6700 4010
Public Relations
ar-cp@ntt.com

Same Day ACH: Debit’s Debut 2017 – Same Day ACH Credits Were Introduced Last Year and This Year, Same Day ACH Debits Take Center Stage – Research and Markets

DUBLIN--(BUSINESS WIRE)--The "Same Day ACH: Debit's Debut" report has been added to Research and Markets' offering.


With both same-day ACH credits and, since September 15, 2917, same-day ACH debits available in the marketplace, this faster form of ACH is finding applicable use cases in both business and consumer applications according to a new research report.

The National Automated Clearing House Association (NACHA), the governing body for ACH, has from time to time rolled out new features to broaden ACH's appeal across channels, most recently faster, same-day transaction processing services. The author's latest research report, Same-Day ACH Debit's Debut, examines the impact that Same Day ACH (SDA) is having on the payments market.

Highlights of the report include:

  • A review the initial results of the launch of same-day credits, rolled out last year
  • Discussion of the most common use cases that have emerged from the introduction of SDA credits
  • Prediction of the likely uses of ACH debits, made available on September 15, 2017
  • Analysis of the impact SDA may have on other legacy payment methods, including wire transfers
  • Consideration of the fraud concerns inherent with SDA
  • Conclusions regarding SDA's impact on real-time payment initiatives.

Key Topics Covered:

1. Executive Summary

2. Introduction

3. Activity Affected

4. SDA Credits Receive a Standing Ovation

5. How Will SDA Debits Perform?

  • Minding the Effective Date
  • Impact to FIs' Wire Business
  • Pricing

6. Fraud: An Ever-Present Concern

7. Conclusions: The Next Act for Same Day ACH

  • Endnotes

For more information about this report visit https://www.researchandmarkets.com/research/d69949/same_day_ach.


Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Credit and Loans

Kulicke & Soffa Reports Fourth Quarter & Fiscal Year 2017 Results

  • Reports $215.9 million of September quarters sales up 48% over the same period last year
  • Delivers $0.51 of September quarter EPS and $1.55 for the year
  • Guides December quarter revenue up 27% over the same period last year

SINGAPORE--(BUSINESS WIRE)--Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC) (“Kulicke & Soffa”, “K&S” or the “Company”) today announced results for its fourth quarter and fiscal year ended September 30, 2017.


Quarterly Results    
     
Fiscal Q4 2017
     

Change vs.
Fiscal Q4 2016

      Change vs.
Fiscal Q3 2017
Net Revenue     $215.9 million       up 48.1%       down 11.5%
Gross Profit     $104.7 million       up 57.2%       down 6.3%
Gross Margin     48.5%       up 280 bps       up 270 bps
Income from Operations     $36.9 million       up 846.2%       up 220.9%
Operating Margin     17.1%       up 1440 bps       up 1240 bps
Net Income     $36.6 million       up 255.3%       up 18.8%
Net Margin     17.0%       up 990 bps       up 440 bps
EPS – Diluted     $0.51       up 240.0%       up 18.6%
               

Dr. Fusen Chen, Kulicke & Soffa's President and Chief Executive Officer, stated, “We have made many tactical and organizational improvements throughout fiscal year 2017 that enhance our collective ability to deliver long-term shareholder value. Broad industry expansion combined with our strong market positions and sizable new opportunities resulted in a dramatic demand increase over the same period in the prior year."

During the September quarter the Company introduced newly defined "Capital Equipment" and "Aftermarket Products and Services" segments and refined its global R&D organization to enhance business unit accountability and market responsiveness. The Company did not incur any restructuring related charges due to these changes.

Fiscal Year 2017 Financial Highlights

  • Net revenue of $809.0 million.
  • Gross margin of 46.4%.
  • Net income was $112.0 million or $1.55 per diluted share.
  • Cash, cash equivalents, restricted cash and short-term investments were $608.9 million as at September 30, 2017.
  • The Company repurchased a total of 0.9 million shares of common stock at a cost of $18.2 million.

First Quarter Fiscal 2018 Outlook

The Company currently expects net revenue in the first fiscal quarter of 2018 ending December 30, 2017 to be approximately $185 million to $195 million, an increase of 27% over the same period in the prior year.

Looking forward, Dr. Fusen Chen commented, "We continue to seek out meaningful new growth opportunities while extending existing market positions. Our ability to deliver value is further enhanced by our expanding portfolio, meaningful partnerships, and refinements to our sales and R&D organizations."

Semiconductor unit production, a proxy for equipment demand, is expected to grow at 11.8% sequentially in calendar year 2017. The Company anticipates that in the longer-term, semiconductor unit production will grow at an 8.9% CAGR through calendar 2021, materially higher than the previously completed four-year period CAGR of 3.4%. Looking ahead, the Company's products continue to be aligned with several of the fastest growing end-applications, including sensors, LED and NAND flash memory.

Earnings Conference Call Details

A conference call to discuss these results will be held today, November 14, 2017, beginning at 8:00am (EST). To access the conference call, interested parties may call +1-877-407-8037 or internationally +1-201-689-8037. The call will also be available by live webcast at investor.kns.com.

A replay will be available from approximately one hour after the completion of the call through November 21, 2017 by calling toll-free +1-877-660-6853 or internationally +1-201-612-7415 and using the replay ID number of 13672443. A webcast replay will also be available at investor.kns.com.

About Kulicke & Soffa

Kulicke & Soffa (NASDAQ: KLIC) is a leading provider of semiconductor packaging and electronic assembly solutions supporting the global automotive, consumer, communications, computing, and industrial segments. As a pioneer in the semiconductor space, K&S has provided customers with market leading packaging solutions for decades. In recent years, K&S has expanded its product offerings through strategic acquisitions and organic development, adding advanced packaging, electronics assembly, wedge bonding and a broader range of expendable tools to its core offerings. Combined with its extensive expertise in process technology and focus on development, K&S is well positioned to help customers meet the challenges of packaging and assembling the next-generation of electronic devices (www.kns.com).

Caution Concerning Results and Forward Looking Statements

In addition to historical statements, this press release contains statements relating to future events and our future results. These statements are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, and include, but are not limited to, statements that relate to our future revenue, sustained, increasing, continuing or strengthening demand for our products, replacement demand, future growth opportunities, our research and development efforts, our ability to control costs, and our ability to identify and realize new growth opportunities within segments, such as automotive and industrial as well as surrounding technology adoption such as system in package and advanced packaging techniques. While these forward-looking statements represent our judgments and future expectations concerning our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to: the risk that customer orders already received may be postponed or canceled, generally without charges; the risk that anticipated customer orders may not materialize; the risk that our suppliers may not be able to meet our demands on a timely basis; the volatility in the demand for semiconductors and our products and services; the risk that identified market opportunities may not grow or developed as we anticipated; volatile global economic conditions, which could result in, among other things, sharply lower demand for products containing semiconductors and for the Company’s products, and disruption of capital and credit markets; the risk of failure to successfully manage our operations; the possibility that we may need to impair the carrying value of goodwill and/or intangibles established in connection with one or more of our prior acquisitions; acts of terrorism and violence; risks, such as changes in trade regulations, currency fluctuations, political instability and war, which may be associated with a substantial non-U.S. customer and supplier base and substantial non-U.S. manufacturing operations; and the factors listed or discussed in Kulicke and Soffa Industries, Inc. 2016 Annual Report on Form 10-K and our other filings with the Securities and Exchange Commission. Kulicke and Soffa Industries, Inc. is under no obligation to (and expressly disclaims any obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

     

KULICKE & SOFFA INDUSTRIES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share and employee data)

(Unaudited)

 
Three months ended Twelve months ended

September 30,
2017

 

October 1,
2016

September 30,
2017

 

October 1,
2016

Net revenue 215,892 145,844 809,041 627,192
Cost of sales 111,153   79,223   433,995   340,463  
Gross profit 104,739   66,621   375,046   286,729  
Operating expenses:
Selling, general and administrative 36,617 29,778 131,015 124,706
Research and development 27,698 22,781 100,203 92,374
Impairment charges 35,207
Amortization of intangible assets 1,989 1,665 6,554 6,661
Restructuring 1,531   8,484   3,813   10,449  
Total operating expenses 67,835   62,708   276,792   234,190  
Income from operations 36,904

3,913

98,254 52,539
Other income (expense):
Interest income 1,989 1,023 6,491 3,318
Interest expense (272 ) (268 ) (1,059 ) (1,107 )
Income from operations before income taxes 38,621 4,668 103,686 54,750
Share of results of equity-method investee, net of tax (197 ) (190 )
Income taxes expense / (benefit) 2,242   (5,661 ) (8,135 ) 7,638  
Net income $ 36,576   $ 10,329   $ 112,011   $ 47,112  
 
Net income per share:
Basic $ 0.52   $ 0.15   $ 1.58   $ 0.67  
Diluted $ 0.51   $ 0.15   $ 1.55   $ 0.67  
 
Weighted average shares outstanding:
Basic 70,742 70,404 70,906 70,477
Diluted 72,071 71,017 72,063 70,841
 
 
                Three months ended   Twelve months ended
Supplemental financial data:

September 30,
2017

 

October 1,
2016

September 30,
2017

 

October 1,
2016

Depreciation and amortization $ 4,518 $ 4,009 $ 16,257 $ 16,230
Capital expenditures 3,779 1,905 25,688 6,301
Equity-based compensation expense:
Cost of sales 119 98 463 421
Selling, general and administrative 1,652 1,223 9,015 3,244
Research and development 481   473   2,244   2,065
Total equity-based compensation expense $ 2,252   $ 1,794   $ 11,722   $ 5,730
 
 
                          As of

September 30,
2017

 

October 1,
2016

Backlog of orders1 190,702 87,200
Number of employees 3,055 2,389

1. Represents customer purchase commitments. While the Company believes these orders will proceed, they are generally cancellable by customers without penalty.

 

KULICKE & SOFFA INDUSTRIES, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

 
As of
September 30, 2017   October 1, 2016
ASSETS
CURRENT ASSETS
Cash and cash equivalents $ 392,410 $ 423,907
Restricted cash 530
Short-term investments 216,000 124,000

Accounts and notes receivable, net of allowance for doubtful accounts of $79 and
$506 respectively

198,480 130,455
Inventories, net 122,023 87,295
Prepaid expenses and other current assets 23,939   15,285  
TOTAL CURRENT ASSETS 953,382 780,942
 
Property, plant and equipment, net 67,762 50,342
Goodwill 56,318 81,272
Intangible assets 62,316 50,810
Deferred income taxes 27,771 16,822
Equity investments 1,502
Other assets 2,056   2,256  
TOTAL ASSETS $ 1,171,107   $ 982,444  
 
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable $ 51,354 $ 41,813
Accrued expenses and other current liabilities 132,314 63,954
Income taxes payable 16,780   12,830  
TOTAL CURRENT LIABILITIES 200,448 118,597
 
Financing obligation 16,074 16,701
Deferred income taxes 26,779 27,697
Other liabilities 14,870   12,931  
TOTAL LIABILITIES 258,171   175,926  
 
SHAREHOLDERS' EQUITY
Common stock, no par value 506,515 498,676
Treasury stock, at cost (157,604 ) (139,407 )
Retained earnings 561,986 449,975
Accumulated other comprehensive gain/ (loss) 2,039   (2,726 )
TOTAL SHAREHOLDERS' EQUITY $ 912,936   $ 806,518  
 
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 1,171,107   $ 982,444  
 
 
       

KULICKE & SOFFA INDUSTRIES, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 
Three months ended Twelve months ended

September 30,
2017

 

October 1,
2016

September 30,
2017

 

October 1,
2016

Net cash provided by operating activities 68,144 33,949 136,310 68,407

Net cash used in investing activities, continuing
operations

(108,615 ) (125,526 ) (145,199 ) (129,165 )

Net cash used in financing activities, continuing
operations

(21,879 ) (291 ) (22,684 ) (14,486 )

Effect of exchange rate changes on cash and cash
equivalents

(597 ) (353 ) 76   537  
Changes in cash and cash equivalents (62,947 ) (92,221 ) (31,497 ) (74,707 )
Cash and cash equivalents, beginning of period 455,357   516,128   423,907   498,614  
Cash and cash equivalents, end of period $ 392,410   $ 423,907   $ 392,410   $ 423,907  
 
Restricted cash 530 530
Short-term investments 216,000   124,000   216,000   124,000  

Total cash, cash equivalents, restricted cash and
short-term investments

$ 608,940   $ 547,907   $ 608,940   $ 547,907  


Contacts

Kulicke & Soffa Industries, Inc.
Joseph Elgindy, +1-215-784-7518
Investor Relations & Strategic Initiatives
F: +1-215-784-6180

TrendForce Projects Global Smartphone Production for 4Q17 to Grow by 6.3% YoY as iPhone X Drives Quarterly Total to Its Peak for the Year

TAIPEI, Taiwan--(BUSINESS WIRE)--#2017SmartphoneProduction--TrendForce’s latest analysis of the global smartphone market finds that sales are growing again due to the effects of the year-end busy season. The global smartphone production volume for the third quarter of 2017 totaled 384 million units, registering a year-on-year increase of 6%. Chinese brands together posted a much higher year-on-year growth of 20%. In terms of ranking by production volume, Samsung, Apple, Huawei, OPPO and Vivo still held their respective positions in the top five for the third quarter, while Xiaomi followed at sixth place.


For this fourth quarter, TrendForce estimates that the global smartphone production volume will reach its peak for 2017 with a total of 425 million, up 6.3% year on year. Additionally, the global total for the entire 2017 is currently estimated at 1.46 billion units.

Samsung’s production volume reached its peak for this year in the third quarter and is projected to fall this fourth quarter due to competition from iPhone X

In terms of market performances of the various brands, the leader Samsung has suffered some setbacks in China, and the brand’s share of total sales in that market has been falling this year. Nevertheless, Samsung has a comprehensive smartphone lineup covering all market segments from the low-end to the mid-range and the high-end. Furthermore, the company has established a wide and deep network of sales channels across the globe. Therefore, Samsung is still able to produce 75 million to 80 million units on average every quarter.

In the third quarter, Samsung’s smartphone production rose on the back of the release of the Galaxy Note 8 series and the continuous strong sales of the Galaxy J series in the mid-range and low-end markets. Samsung’s total volume for the period reached 81 million units, representing the highest point for the brand this year. Samsung thus retained its top place in the third-quarter ranking.

Samsung is expected to slightly scale back the production of its high-end models in the fourth quarter as the brand is seeing the sales of its smartphones being squeezed by the strong demand for Apple’s latest iPhone devices. TrendForce estimates that Samsung’s fourth-quarter total volume will come to 77 million units, a 5% drop from the third quarter.

Apple managed to advance its iPhone production volume by just 3% in the third quarter compared with the second quarter. On the whole, iPhone 8 and 8 Plus helped sustained Apple’s production during the third quarter. As for highly anticipated iPhone X, the yield rates of its key components (e.g. Wi-Fi modules and 3D sensing modules) have been lower than expected, thus delaying production of the device. With the limited support from iPhone X, Apple was not able to significantly raise its total volume.

On the other hand, TrendForce estimates that the iPhone production volume for this fourth quarter will reach 81 million units with iPhone X accounting for 33% of the total. TrendForce expects a surge of iPhone X production that will last through the first half of 2018.

The deal between HTC and Google did not significantly influence the respective production volumes of these two brands in the third quarter. However, TrendForce believes that HTC’s smartphone production will continue to contract in the future. Google conversely could raise the market share of its branded smartphones with the additional R&D capability that it has acquired. HTC’s smartphone production volume for the third quarter plunged by 46% compared with the second quarter since the company offers fewer models than before and lacks differentiations from competitors. Google by contrast saw the production volume of its branded smartphones went up by around 40% from the second quarter due to the release of Pixel 2 and 2 XL in October. Google is expected to post sequential increase for this fourth quarter as well.

Chinese brands together accounted for 56% of the global production in third quarter with a total volume of 214 million units

Chinese brands made gains in the third quarter due to demand generated by the releases of their flagship devices during the year’s second half. Huawei’s smartphone product volume rose by 9% from the second quarter and could reach a total of 45 million units for this fourth quarter because of the year-end seasonal demand. Huawei’s annual total for 2017 is currently estimated around 150 million units.

Huawei’s smartphone strategy for this year is to focus on selling its high-end, high-margin models while reducing the number of its low-price, entry-level models in the lineup. Huawei’s total production volume for the second half of 2017 will register similar growth compared with the result of the same period in 2016. On the other hand, Huawei continues to expand its presence in the overseas markets and will remain as the world’s third-largest smartphone maker and the leader among the Chinese smartphone brands for 2017.

OPPO and Vivo were respective second and third in the third-quarter ranking of the Chinese brands. Their combined production volume grew by an average rate of 5% from the second quarter. Going forward, the combined volume of the two brands in fourth quarter is expected to be on par with their third-quarter result. In terms of annual performance, their combined volume will grow substantially with the average rate estimated at 20%. OPPO and Vivo’s success is mainly attributed to having sales channels that extend to the remote areas of China and their ongoing expansions in the overseas markets.

With the help of its latest model Mi MIX 2, Xiaomi produced 25.5 million units for the third quarter and was just behind Vivo in terms of global market share. In India, Xiaomi continues to work closely with the local mobile operators as it struggles with Samsung for dominance in the country’s mid-range and high-end market segments. TrendForce estimates Xiaomi’s fourth-quarter production volume will grow by 10% from the third quarter to 28 million units.

With regard to the global production volume for the fourth quarter of 2017, TrendForce estimates a growth of 10.5% from the third quarter’s total because of the strong sales of the latest iPhone devices. Looking ahead to 2018, the global smartphone market will stay on a path to gradual saturation. TrendForce believes that the abilities to control rising component costs and expand overseas channels will be key factors affecting the performances of respective brands.

For the further details of the press release and the following table – Top Six Global Smartphone Brands by Worldwide Market Share, 1Q17~4Q17 – please visit:

http://press.trendforce.com/press/20171109-3017.html

About TrendForce (www.trendforce.com)

TrendForce is a global provider of market intelligence on the technology industries. Having served businesses for over a decade, the company has built up a strong membership base of 500,000 subscribers residing the technology and financial services sectors. TrendForce has established a reputation as an organization that offers insightful and accurate analysis of the technology industry through five major research divisions: DRAMeXchange, WitsView, LEDinside, EnergyTrend and Topology Research Institute. Founded in Taipei, Taiwan in 2000, TrendForce has extended its presence in China since 2004 with offices in Shenzhen and Beijing.


Contacts

TrendForce
Ms. Pinchun Chou, +886-2-8978-6488 ext.669
pinchunchou@TrendForce.com
or
Ms. Lindsay Hou, +886-2-8978-6488 ext.667
Lindsayhou@TrendForce.com

RGA Reinsurance Company Selected as Life Reinsurer of the Year by Asia Insurance Review

Leading insurance industry publication honors RGA at 21st Asia Insurance Industry Awards

ST. LOUIS--(BUSINESS WIRE)--RGA Reinsurance Company, a subsidiary of Reinsurance Group of America, Incorporated (NYSE: RGA), a leading global life reinsurer, today announced it was selected as “Life Reinsurer of the Year” in the 2017 Asia Insurance Industry Awards sponsored by Asia Insurance Review.


RGA was recognized for “demonstrating leadership in Asia’s life (re)insurance industry through innovation and thought leadership, and enhancing the stability and security of the industry while boosting the image of the profession.” The company was selected for the award by a distinguished panel of judges representing the insurance and reinsurance industries.

“We believe our innovative initiatives and insurance solutions are successfully making life insurance more inclusive, innovative, relevant, and exciting,” said Tony Cheng, Executive Vice President, Head of Asia, RGA Reinsurance Company. “And we are proud to be recognized by Asia Insurance Review for this great honor.”

RGA was also recently named recipient of the Outstanding Reinsurance Scheme Award at the 2017 Hong Kong Insurance Awards organized by the Hong Kong Federation of Insurers (HKFI). This marked the first year the HKFI broadened its annual industry honors to include reinsurers.

About RGA

Reinsurance Group of America, Incorporated (RGA), a Fortune 500 company, is among the leading global providers of life reinsurance and financial solutions, with approximately $3.3 trillion of life reinsurance in force and assets of $58.7 billion as of September 30, 2017. Founded in 1973, RGA today is recognized for its deep technical expertise in risk and capital management, innovative solutions, and commitment to serving its clients. With headquarters in St. Louis, Missouri and operations in 26 countries, RGA delivers expert solutions in individual life reinsurance, individual living benefits reinsurance, group reinsurance, health reinsurance, facultative underwriting, product development, and financial solutions. To learn more about RGA and its businesses, visit the company’s website at www.rgare.com.


Contacts

Reinsurance Group of America, Incorporated
Lynn Phillips, 636-736-2351
Vice President, Corporate Communications
lphillips@rgare.com
or
Lizzie Curry, 636-736-8521
Public Relations Manager
lizzie.curry@rgare.com

Kulicke & Soffa Schedules Fourth Quarter & Full Year 2017 Conference Call for 8AM EST, November 14th, 2017

SINGAPORE--(BUSINESS WIRE)--Kulicke & Soffa Industries, Inc. (NASDAQ: KLIC) (“Kulicke & Soffa”, “K&S” or the “Company”), a global leader in the design and manufacture of semiconductor, LED and electronic assembly equipment, today announced a conference call is scheduled to discuss the Company's fourth quarter and full year 2017 financial results, and its business outlook on Tuesday, November 14, 2017 at 8:00am EST. The Company will issue its fourth quarter 2017 results prior to the conference call.


To access the conference call, interested parties may call +1-877-407-8037 or internationally +1-201-689-8037. A live webcast will also be available at investor.kns.com.

A replay will be available from approximately one hour after the completion of the call through November 21, 2017 by calling toll-free +1-877-660-6853 or internationally +1-201-612-7415 and using the replay ID number of 13672443. A webcast replay will also be available at investor.kns.com.

About Kulicke & Soffa

Kulicke & Soffa (NASDAQ: KLIC) is a leading provider of semiconductor packaging and electronic assembly solutions supporting the global automotive, consumer, communications, computing, and industrial segments. As a pioneer in the semiconductor space, K&S has provided customers with market leading packaging solutions for decades. In recent years, K&S has expanded its product offerings through strategic acquisitions and organic development, adding advanced packaging, electronics assembly, wedge bonding and a broader range of expendable tools to its core offerings. Combined with its extensive expertise in process technology and focus on development, K&S is well positioned to help customers meet the challenges of packaging and assembling the next-generation of electronic devices.


Contacts

Kulicke & Soffa Industries, Inc.
Joseph Elgindy
Investor Relations & Strategic Initiatives
P: +1-215-784-7518
F: +1-215-784-6180
investor@kns.com
or
Marilyn Sim
Public Relations
P: +65 6880 9309
F: +65 6880 9580
msim@kns.com

Astellas Reports First Half FY2017 Financial Results, Revises Fiscal Year Outlook

  • Sales (-1.8%) and core operating profit (-18.1%) decreased due to the impact of certain items such as the transfer of the global dermatology business in April 2016 and the transfer of long-listed products in Japan in April 2017. Excluding these items as well as the foreign exchange rate impact, sales were -1.9% and core operating profit was -2.7% respectively.
  • Sales of key global products such as XTANDI® (enzalutamide) for the treatment of prostate cancer and overactive bladder (“OAB”) treatments Betanis® / Myrbetriq® / BETMIGA® (mirabegron) grew.
  • Astellas continues to create solid and resilient growth.


TOKYO--(BUSINESS WIRE)--Astellas Pharma Inc. (TOKYO:4503) (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced the financial results for the first six months of fiscal year 2017, ending March 31, 2018 (“FY2017”).

“Key global products XTANDI and Betanis / Myrbetriq / BETMIGA (mirabegron) continued to demonstrate steady growth in the first six months of FY2017, and milestones such as the positive results from the Phase 3 PROSPER trial of enzalutamide in non-metastatic castration resistant prostate cancer patients demonstrate that our development activities are progressing steadily. Furthermore, continuous resource allocation is being made with the aim of realizing sustainable growth over the medium- and long-terms,” said Yoshihiko Hatanaka, president and CEO, Astellas. “We remain committed to creating innovative medical solutions and delivering value for patients and all stakeholders, as we continue to advance our strategic plan through maximizing the product value, creating innovation and pursuing operational excellence.”

 

Consolidated Financial Results (April 1, 2017 – September 30, 2017) (core basis)

 (Millions of yen)

    First six months of FY2016   First six months of FY2017   Change
(%)
Sales 651,673 639,754

-11,919
(-1.8%)

Core operating profit 166,455 136,353

-30,102
(-18.1%)

Core profit for the period   120,569   106,638  

-13,932
(-11.6%)

 

Quarterly Revenue Highlights

Sales in the first six months of FY2017 decreased by 1.8% compared to those in the corresponding period of the previous fiscal year (“year-on-year”) to ¥639.8 billion due to the impact of certain items such as the transfer of the global dermatology business in April 2016 and the transfer of long-listed products in Japan in April 2017.

  • Oncology franchise

Sales of XTANDI® increased by 11.4% year-on-year to ¥140.3 billion. Sales in the United States (“U.S.”) remained largely unchanged year-on-year, but sales grew steadily in Japan, the Americas excluding the U.S., EMEA1 and the Asia and Oceania region.

  • Urology OAB franchise

Sales of Betanis® / Myrbetriq® / BETMIGA® increased by 26.0% year-on-year to ¥57.6 billion. Sales increased in all regions: Japan, the Americas, EMEA and the Asia and Oceania region. Sales of Vesicare®, however, decreased by 16.9% year-on-year to ¥49.7 billion.

  • Transplantation franchise

Sales of Prograf® (tacrolomis) increased by 5.4% year-on-year to ¥99.3 billion, and continued to grow in the EMEA and the Asia and Oceania regions.

  • Other new and key products

In the Japanese market, continued growth was achieved for products such as Celecox® (celecoxib) for the treatment of inflammation and pain, Symbicort® (budesonide and formoterol fumarate dihydrate) for the treatment of bronchial asthma, Suglat® (ipragliflozin) for the treatment of type 2 diabetes, and Cimzia® (certolizumab pegol) for the treatment of adult patients with rheumatoid arthritis. Meanwhile, we have been steadily working to penetrate the market with our launch of Repatha® (evolocumab) for the treatment of hypercholesterolemia, which occurred in April 2016, and of LINZESS® (linaclotide) for the treatment of irritable bowel syndrome with constipation, which occurred in March 2017. In the Americas, sales of azole antifungal CRESEMBA® (isavuconazonium sulfate) grew.

 

(Billions of yen)

    First six months of FY2016   First six months of FY2017   Change
Oncology franchise 153.9 167.8 +9.1%
XTANDI® 126.0 140.3 +11.4%
Urology OAB franchise 105.5 107.3 +1.7%
Vesicare® 59.8 49.7 -16.9%
Betanis® / Myrbetriq® / BETMIGA® 45.7 57.6 +26.0%
Transplantation franchise   94.2   99.3   +5.4%
 

Sales by Region2

Sales in Japan, the Americas and EMEA decreased, while sales in Asia and Oceania increased. As for the Japanese market, sales decreased by 12.5% year on year to ¥194.1 billion largely due to the impact of transferring 16 long-listed products in April 2017, and the introduction of generics for Micardis® (telmisartan) for the treatment of hypertension in June 2017. Meanwhile in EMEA, sales decreased due to the impact of transferring the dermatology business in April 2016, yet sales showed an increase when calculated excluding this impact.

FY2017 Guidance

The company has upwardly revised its forecasts for sales, core operating profit and core profit for the year from the figures announced in April 2017 (“initial forecast”) based on the financial results for the first six months of FY2017 and the trend of foreign exchange rates. Revised expected exchange rates are anticipated to cause a ¥20.2 billion increase in sales and a ¥3.8 billion increase in core operating profit compared to if the expected exchange rates of the initial forecast were applied.

 

Consolidated Full-year Business Forecasts (core basis)

(Millions of yen)

    FY2016

Full-year results

  FY2017

Full-year forecasts

  Change
(%)
Sales 1,311,665 1,297,000

-14,665
(-1.1%)

Core Operating profit 274,554 258,000

-16,554
(-6.0%)

Core Profit for the year   213,343   201,000  

-12,343
(-5.8%)

 

NOTE: For further information on the results including on a full basis, please refer to the reference documents: Financial Results, Supplementary Documents, Overview of R&D Pipeline and Presentation Material for the Financial Information Meeting available on the Astellas website. https://www.astellas.com/en/investors/ir-library

Strategic Quarterly Highlights

Astellas continues to create sustainable growth over the mid-to-long term through the pursuit of three main strategies – “Maximizing the Product Value,” ” Creating Innovation” and “Pursuing Operational Excellence.” The company achieved multiple accomplishments as outlined below.

Maximizing the Product Value

  • Continued to maximize the growth of the Oncology franchise centered on XTANDI® and the Urology OAB franchise including Vesicare® and Betanis® / Myrbetriq® / BETMIGA® with new launches across various countries and growth in sales.

Creating Innovation

The following lists the main development advances achieved during the first six months of FY2017:

  • Announced the Phase 3 PROSPER trial evaluating XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) versus ADT alone in patients with non-metastatic castration-resistant prostate cancer met its primary endpoint of improved metastasis-free survival in September 2017.
  • Submitted an application for marketing approval of fidaxomicin for the treatment of infectious enteritis caused by Clostridium difficile in Japan in July 2017.
  • Repatha® SC Injection 420 mg Auto mini doser was approved in Japan in August 2017.
  • Submitted a supplemental new drug application for marketing approval of linaclotide (generic name, brand name: Linzess® Tablets 0.25 mg), for the additional indication of chronic constipation (other than constipation associated with organic disorders) in Japan in September 2017

Pursuing Operational Excellence

  • Announced that as of October 1, 2017, Maruho Co., Ltd will succeed the marketing approval in Japan from Astellas, for anti-atopic dermatitis agent Protopic® Ointment (July 2017).
  • Announced the decision to wind down the research operations of Agensys, Inc.(U.S.) (July 2017).

(1) EMEA: Europe, the Middle East and Africa
(2) Sales by Region: based on location of sellers

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.
Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.


Contacts

Contacts for inquiries or additional information:
Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201
FAX: +81-3-5201-7473
or
US Media:
Astellas US LLC
Tarsis Lopez, 224-205-8833
tarsis.lopez@astellas.com

TrendForce Says Samsung Could Increase Competition in DRAM Market Next Year by Expanding Its Production Capacity; Supply May Not Remain Tight for Long

TAIPEI, Taiwan--(BUSINESS WIRE)--#18nm--During the recent two years, limited increase in production capacity and challenges related to technology migration have slowed down the growth of DRAM supply, according to DRAMeXchange, a division of TrendForce. Contract prices of DRAM products began to climb in the second half of 2016, particularly driven by the strong demand in the year-end busy season. The DRAM market since then has continued to see surging prices. However, there are reports that Samsung is considering expanding its production capacity to increase competition and raise the barrier for market entry. Thus, there is a possibility that the tight supply for DRAM may end sooner than originally anticipated.


“The average contract price of mainstream 4GB DDR4 PC DRAM modules, for example, has soared from US$13 at the end of second quarter of 2016 to the current US$30.5 in the fourth quarter of 2017,” said Avril Wu, research director of DRAMeXchange. “This represents an increase of 130% over six consecutive quarters.”

Profits of major DRAM suppliers have also expanded significantly on account of the booming market. Currently, the top supplier Samsung has an operating margin of 59%, while operating margins of SK Hynix and Micron are also impressive, respectively at 54% and 44%. The outlook for the fourth quarter of 2017 can be summed up as higher contract prices and higher profits.

Samsung’s capacity expansion plan intends to raise barrier against potential market entrants

With the DRAM market being an oligopoly, the three dominant suppliers theoretically would want to maintain the status quo as to maximize their profits. Nonetheless, SK Hynix and Micron are now flushed with cash after benefiting from several quarters of rising prices, and they are also in a great position to improve their competitiveness. SK Hynix is now transitioning to the 18nm node and will be building its second fab in the Chinese city of Wuxi next year. Meanwhile, with the cash and resources at hand, SK Hynix will be able to proceed with its plans smoothly and on schedule. As for Micron, its rising stock price has given the company an opportunity to pursue capital increase by cash. This signals that Micron is preparing to build new fabs, expand production capacity or upgrade its manufacturing technology. The gains made by SK Hynix and Micron as well as their recent activities are unlikely to have escape Samsung’s notice. Therefore, Samsung may in response expand its DRAM production capacity to main its lead in the market.

Capacity building on the surface is about alleviating the current tight supply situation but the underlying motive behind such a move is to keep prices from going up further. If Samsung chooses this strategy, the short-term effect will be an increase in depreciation cost that will also erode the profitability of its DRAM business. However, Samsung’s ultimate goal to ensure its long-term dominance in the market in terms of having an enormous production capacity and being ahead of its competitors’ technologies by one to two years.

Additionally, China’s memory industry continues to take shape and is expected to enter its formative stage of development in 2018. To forestall Chinese DRAM and NAND Flash makers from catching up significantly, Samsung could raise its production capacities for these products and engage in aggressive pricing. Potential market entrants will not be able to expand their production capacities and improve their technologies on schedule if they are under heavy financial pressure.

Projected bit supply growth in the global DRAM market for 2018 has been raised to 22.5% as Micron and SK Hynix may follow Samsung in capacity expansion

DRAMeXchange reports that Samsung is considering raising its DRAM production by altering the plan for its new Pyeongtaek facility and expanding the capacity of its Line 17 fab. A part of the second floor of the Pyeongtaek facility may be set aside for fabricating DRAM wafers rather than NAND Flash wafers as originally intended. It would also be probable that DRAM production at the Pyeongtaek facility will be wholly on the 18nm process. As for Line 17, there is still some space for further capacity expansion.

If Samsung follows through with the aforementioned plans, its DRAM output for the entire 2018 is forecast to increase by 80,000 to 100,000 wafers. Under the same scenario, Samsung’s total DRAM production capacity would also shoot up from 390,000 wafers per month at the end of 2017 to nearly 500,000 wafers per month by the end of 2018. In terms of annual bit supply growth for 2018, DRAMeXchange originally forecast Samsung’s at 18%. However, the annual growth rate for next year could go up to 23% if Samsung carries out capacity expansion.

Taking Samsung’s plans into account, the annual bit supply growth in the global DRAM market for 2018 could reach 22.5%, which is noticeably higher compared with the estimated rate of 19.5% for 2017. This also suggests that the supply gap may be filled next year. Furthermore, SK Hynix and Micron will likely to follow Samsung’s initiative and expand their capacities to maintain their market shares. The activities from the three major suppliers will add new variables into the market.

DRAMeXchange’s latest analysis finds that Samsung’s capacity expansion plans, while could bring relief to the current tight supply situation, are mainly about checking the runaway profit growths of competitors. With supply increasing, profitability of suppliers will return to their usual levels. Furthermore, the NAND Flash market will likely see a milder oversupply situation than initially expected for next year if major memory makers focus more of their investments on DRAM production. In this case, the slide in the average selling price of NAND Flash may also become more moderate. Thus, Samsung’s capacity building could impact DRAM market in 2018, but it might not be negative to the long-term development of the industry as a whole.

For further details of this press release, including the following figures - - (Figure 1) Forecast Changes in Global DRAM Production Capacity and (Figure 2) Forecast Changes in Samsung's DRAM Production Capacity - - please visit:

http://press.trendforce.com/press/20171030-3006.html

About TrendForce (www.trendforce.com)

TrendForce is a global provider of market intelligence on the technology industries. Having served businesses for over a decade, the company has built up a strong membership base of 500,000 subscribers residing the technology and financial services sectors. TrendForce has established a reputation as an organization that offers insightful and accurate analysis of the technology industry through five major research divisions: DRAMeXchange, WitsView, LEDinside, EnergyTrend and Topology Research Institute. Founded in Taipei, Taiwan in 2000, TrendForce has extended its presence in China since 2004 with offices in Shenzhen and Beijing.


Contacts

TrendForce
Ms. Pinchun Chou
Tel: +886-2-8978-6488 ext.669
pinchunchou@TrendForce.com
or
Ms. Lindsay Hou
Tel: +886-2-8978-6488 ext.667
Lindsayhou@TrendForce.com

Hoya Reports Second Quarter Results; Record Half Year Results

TOKYO--(BUSINESS WIRE)--Hoya Corporation (TOKYO: 7741) today announced financial results for the second quarter ended September 30, 2017.


During the quarter, revenue of the HOYA Group increased 18.2% year on year, reaching 135,772 million yen. Pre-tax profit amounted to 32,868 million yen with 26,767 million yen in profit, representing increases of 3.9% and 7.9%, respectively.

In the Life Care segment, sales of eyeglass lenses rose, mainly overseas and in response to business acquisitions. Medical endoscopes experienced improved sales, pushed mainly by performance in Europe and Asia. New products drove sales of intraocular lenses as well. As a result, the Life Care segment as a whole reported higher sales year on year.

The Information Technology segment also reported higher revenues year on year, driven by stronger demands in semiconductor devices and glass substrates for hard disk drives. Imaging-related product sales increased as well due to an expansion of new applications.

For the six months ended September 30, 2017, HOYA posted record revenues of 262,930 million yen and record profit for the term of 51,960 million yen, representing increases of 14.3% and 21.4%, respectively.

“The Life Care segment delivered sales increase of 9.4% without exchange gain this quarter,” said Hiroshi Suzuki, president and chief executive officer of HOYA. “We expect the segment profitability to improve in the second half as post-merger integration completes.”

HOYA also announced the interim dividends of 30 yen per share of common stock.

 

Summary of Consolidated Financial Statement

(Millions of Yen: Rounded to the nearest million)
      Three months ended   Variance   Six months ended   Variance
          Sept./16   Sept./17 (%) Sept./16   Sept./17 (%)
Revenue 114,865 135,772 18.2 230,030 262,930 14.3
Profit before tax 31,637 32,868 3.9 53,911 63,416 17.6
Profit for the term 24,819 26,767 7.9 42,797 51,960 21.4
Basic earnings per share(yen)   63.42   70.11   ---   108.62   134.81   ---

*Results are preliminary and unaudited.

 

The full reports are available at: www.hoya.com

About HOYA

Founded in 1941 in Tokyo, Japan, Hoya is a global med-tech company and the leading supplier of innovative high-tech and medical products. Hoya is active in the fields of healthcare and information technology providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses as well as key components for semiconductor devices, LCD panels and HDDs. With over 150 offices and subsidiaries worldwide, Hoya currently employs a multinational workforce of 36,000 people. For more information, please visit http://www.hoya.com.


Contacts

Hoya Group
Akiko Chiba, +81-3-6911-4824
Public Relation
HOYA-pr@hoya.com

Seoul Semiconductor Achieves Record Quarterly Revenue and Aims for Record Earnings in Fiscal Year 2018

  • Reported third quarter revenues of KrW 305 billion and an operating profit of KrW 30.6 billion increase 14 % quarter-over-quarter and 24 % year-over-year respectively as a result of rising sales across all business divisions
  • The increased revenue and profit are attributable to its portfolio of differentiated technologies and patents, which are gaining global wide recognition from its custom

ANSAN, South Korea--(BUSINESS WIRE)--$KOSDAQ046890 #LED--Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a market leader in LED (light emitting diode) design and manufacturing, today announced consolidated third-quarter revenues of KrW 305 billion.



The rise in consolidated revenue was a result of strong sales of its differentiated technologies Acrich MJT, Wicop, UCD and filament LED. Within the lighting division, more than one-third of its customers have already shifted to adopt Acrich MJT, which is expected to account for over 50 % of sales in general lighting next year. Filament LEDs are rapidly becoming popular in the decorative lighting market, where they are replacing conventional LEDs.

Sales grew in the Display segment due to strong adoption of Acrich, enabling optimal local dimming in premium UHD TVs (Ultra-High Definition Televisions), and UCD that brings exceptional color rendering to displays.

The package-free LED Wicop, featuring greatly enhanced brightness and enabling slim displays, already accounts for double-digit overall sales. The application of Wicop has gone beyond automotive daytime running lights (DRLs) and is now being used in automotive headlamps. In addition to rising sales of its differentiated products, the over 30 %+ year-over-year rise in automotive lighting sales in the third quarter proved highly profitable for the company.

The company’s third quarter operating profit of KrW 30.6 billion marks a remarkable growth of 27 % quarter-over-quarter and 54 % year-over-year despite a continued decline of the average selling price (ASP). Sales of high-end products due to their differentiated technologies and the company’s continued cost and process innovations have greatly contributed to improving bottom line figures. Seoul expects its new factory in Vietnam and the implementation of smart factory systems to further strengthen cost innovations for the future.

Company outlook

The company forecasts revenue guidance of KrW 270 to 290 billion for the fourth quarter. This figure is relatively high considering the exceptional third quarter results and the fact that the fourth quarter is typically off-season for LED manufacturers.

The company’s Chief Financial Officer Sangbum Kim stated that SunLike, a new LED technology which produces light closely matches the spectrum of natural sunlight which was launched at a press conference in Frankfurt, Germany in June, has been very well received with great interest from customers around the world.

The company’s previously launched LED drivers, which integrate invertors into chips, will continue to advance future sales and profit growth.

Kim also stated that the company plans to keep its focus on protecting its customers by continuing to develop differentiated technology and secure intellectual property.

About Seoul Semiconductor:

Seoul Semiconductor develops and commercializes light emitting diodes (LEDs) for automotive, general illumination, specialty lighting, and backlighting markets. As the fourth-largest LED manufacturer globally, Seoul Semiconductor holds more than 12,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; Wicop – a simpler structured package-free LED which provides market leading color uniformity, cost savings at the fixture level with high lumen density and allows design flexibility; NanoDriver Series – World’s Smallest 24W DC LED Drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, includes all AC LED-related technologies from chip to module and circuit fabrication, as well as multi-junction technology (MJT); and nPola, a new LED product based on GaN-substrate technology that achieves over ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers over 90 % NTSC.

For more information about Seoul Semiconductor, please visit http://www.seoulsemicon.com

# Trademarks

Wicop and Acrich are trademarks of Seoul Semiconductor Co., Ltd.

Investor information and additional product details are available on the company website, www.seoulsemiconductor.com

Forward-looking statements:

This press release material contains forward-looking statements which reflect Seoul Semiconductor’s current views with respect to future events and financial performance, which are subject to certain risks and uncertainties which could cause actual results to differ materially from those anticipated. Although Seoul Semiconductor believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be attained. Seoul Semiconductor undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. All financial figures are consolidated unless stated otherwise.


Contacts

Europe
Seoul Semiconductor Europe GmbH
Ariane Heim
Tel: +49 (0)89 450 3690-0
Email: press.eu@seoulsemicon.com
or
North America
Seoul Semiconductor Inc.
David Cox
Tel: +1 (919) 410-9856
Email: David.cox@seoulsemicon.com
or
Asia
Seoul Semiconductor Co., Ltd
Jake Jung
Tel: +82 070.4391.8270
Email: pr@seoulsemicon.com

Eurofins Scientific Donates €1 Million to Mark Its 30-Year Anniversary

40 charities selected by global workforce

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:


Eurofins (Paris:ERF):

Eurofins Scientific (EUFI.PA), the world leader in bioanalytical testing, plans to mark its 30th anniversary by donating €1 million to 40 charities selected by its global workforce. This donation will be in addition to its long-term and ongoing support for several non-governmental organizations (NGOs) including UNICEF and Plan International.

The €1 million donation will target charities that work in areas that, like Eurofins’ testing of foods and pharmaceutical products and of the environment, help make the planet a safer and healthier place to live. The recipient charities fall into five categories: better nutrition, protecting ecosystems, improving health, social entrepreneurship and local communities.

In addition to this financial support, many members of Eurofins’ 30,000-strong workforce will pledge time to volunteer, offer pro bono work and organise events to support their chosen good causes. In each country, volunteer committees were actively involved in choosing organisations that are important to their local area and close to their hearts.

Dr. Gilles Martin, CEO of Eurofins, said: “There is no better way for Eurofins to celebrate its 30th anniversary than sharing some of the results of our success with organizations and initiatives that work to preserve our environment, improve the health and safety of all worldwide, and support the less fortunate.”

He went on to say: “I am fortunate to lead a Company that makes every day a positive contribution to health around the world, and to work with so many leaders, entrepreneurs and team members who share the same passion – advancing science and testing technologies towards a better and safer life for all. Beyond the contribution of our everyday work to this inspiring objective, it is pleasing that our commercial success enables us to support non-profit organisations who also work for these causes.”

He pointed out this donation is in addition to the company’s regular annual donations.

Highlighted below is an example from each country/region of the 40 total initiatives supported by Eurofins and its employees that span across all continents:

In the US, Eurofins’ employees picked Water for People, which works across 9 countries to bring safe water and sanitation to 4 million people.

In Europe, Eurofins is proud to back Médecins Sans Frontières’ (MSF) Mini-lab project, which is developing cheap and portable clinical laboratories to support MSF’s doctors conduct epidemic investigations in developing countries. Eurofins will also co-fund and support the Nutri’Zaza project, which seeks to combat chronic child malnutrition in Madagascar by producing and distributing an affordable highly nutritious food supplement.

In Japan, Eurofins will make a donation to Save Fukushima Orphans, which is dedicated to supporting orphans of the Great East Japan Earthquake. Eurofins also operates a radioactivity measurement competence centre there to assist the local community in assessing the impact of radioactivity linked to the Fukushima disaster.

Our employees in the Nordic region selected the Swedish Society for Nature Conservation (SSNC), which will receive a contribution for its work to protect the marine environment of the Baltic Sea, which is under threat from over fishing, pollutants, micro plastics and eutrophication. Eurofins will also become a partner of the SSNC and share our expertise in analytical testing services to support their environmental work.

In Brazil, Eurofins will donate to Amigos do Bem, an organisation that promotes local development and social inclusion through self-sustaining projects and education efforts.

The additional initiatives supported by Eurofins include:

In Europe, Eurofins will make donations to the Associazione Italiana per la Ricerca sul Cancro (AIRC), the Foundation Gustave Roussy, to Médecins Sans Frontières (MSF) Mini-Lab project, to UNICEF’s “Clean water saves lives” project, to the German Red Cross’s “Food Security Project”, to the Deutscher Kinderhospizverein e.V. (DKHV), to the Duke of Edinburgh (DoE) award, to Allergy UK, to the British Science Association, to the Special Education School of San Rafael, to the Asociación Niños con trasplante hepático (ANiNATH) and to the Federación Española de Bancos de Alimentos, to the EAT Forum, to the Danish organization Walking for Water, to T-Celleforskning, to the Swedish Society for Nature Conservation (SSNC), to Barcode for Life, to Bart de Graaff Foundation for their BIKKELS project, to the Dungarvan branch of the Irish Red Cross, to the South East Simon Community and to the National Children’s Hospital in Tallaght.

In the Americas, Eurofins will make donations to Amigos do Bem, to Americares, to the Conservation Fund, to the Community Action Partnership of Lancaster County, to the Gift of Life Foundation, to the Water for People charity and to the United Service Organizations (USO).

In the APAC region, Eurofins will make donations to the Save Fukushima Orphans project, to the You Dao Foundation, to the Oasis Green Food Bank, to the World Wildlife Fund (WWF) of China, to KidsCan New Zealand, to the Tindall Foundation and to OzHarvest.

For more information, please visit www.eurofins.com

Notes for the editor:

Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 30,000 staff in 400 laboratories across 41 countries, Eurofins offers a portfolio of over 150,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.


Contacts

Investor Relations
Eurofins Scientific
Phone: +32 2 766 1620
E-mail: ir@eurofins.com

Teleperformance in the Philippines Wins Top Employer of the Year at Asia CEO Awards

PARIS--(BUSINESS WIRE)--Regulatory News:


Teleperformance (Paris:RCF), the worldwide leader in outsourced omnichannel customer experience management services, was named Top Employer of the Year at the 2017 Asia CEO Awards. Asia CEO Awards is the largest business awards event in Southeast Asia and brings together senior leadership teams from top corporations to recognize the most accomplished companies and leaders around the region who have demonstrated outstanding achievement and contributions in business and nation-building.

Teleperformance Philippines Managing Director Travis Coates graciously accepted the recognition on behalf of his team, in front of an audience of more than 1,000 peers gathered at the Marriott Grand Ballroom in Pasay City on October 17.

“It’s an honor to receive this award on behalf of our team and to be recognized among this wonderful group of companies. I’m also deeply humbled to lead Teleperformance in the Philippines, which now employs nearly 40,000 Filipinos,” said Coates. “Teleperformance has the most amazing workforce and we work very hard to give them the best possible employee experience. We are also very active in giving back to our communities and we will continue to work even harder to be the kind of employer of choice who ultimately wins awards like this. We truly appreciate this recognition and congratulate all of the winners.”

In the company’s first year of consideration, Teleperformance in the Philippines emerged as the winner of the Top Employer award over several other well-respected companies. All companies considered for the award had to demonstrate excellence across the categories of Management Achievement, Workplace Enhancement, International Recognition, Talent Development, Social Commitment and Work-Life Balance. Teleperformance in the Philippines showed excellence across all categories, particularly in sustained hiring growth, long employee tenure, proactive internal recognition and promotion, strong learning and development programs, diverse workforce, conducive working environment, promotion of work-life balance and implementation of sound corporate social responsibility projects.

Daniel Julien, Chairman and Global CEO, Teleperformance Group, added: "The entire worldwide Teleperformance family is extremely proud of our Teleperformance management team in the Philippines. They wonderfully convey Teleperformance values and our culture of ‘passion for people, commitment to excellence’ while offering the young generation of talented Filipinos a world-class work environment and so many personal development opportunities."

Teleperformance was also named a top finalist for the Corporate Social Responsibility Company of the Year at the Asia CEO Awards for its admirable advocacy programs through its corporate social responsibility arm, Citizen of the World. Citizen of the World focuses on helping sick children and the elderly, as well as facilitating relief operations in times of natural disasters.

Teleperformance commits to be the “personal link” between employees and their careers, and between brands and their customers. In demonstrating this commitment, Teleperformance in the Philippines has successfully grown as an employer of choice for its nearly 40,000-person workforce.

For the past six consecutive years, Teleperformance has received the Frost & Sullivan Asia Pacific Contact Center Outsourcing Service Provider of the Year Award for its significant performance in revenue management, market share, capabilities, and overall contribution to the contact center industry. In addition, Teleperformance in the Philippines was awarded as Outstanding Employer and Outstanding Community Project of the Year 2017 by the Philippine Economic Zone Authority (PEZA) and has been recognized by Aon Hewitt as a Best Employer in the Philippines.

ABOUT TELEPERFORMANCE IN THE PHILIPPINES

Teleperformance began operations in the Philippines in 1996 and has grown to become a preferred offshore contact center outsourcing option. The company employs around 40,000 people in the country and operates nearly 30,000 workstations in 18 delivery centers located across Metro Manila, Antipolo, Baguio, Bacolod, Cebu, Cagayan de Oro, and Davao.

In 2017, Teleperformance marked its 21st year of continued excellence and leadership in the Philippines. This milestone highlights the company’s commitment to steadily provide the best employment experience for Filipinos, proactively support the nation’s ICT-BPO sector, and uphold its socio-civic engagements to create a difference in the lives of the Philippine community.

ABOUT TELEPERFORMANCE

Teleperformance (RCF – ISIN: FR0000051807 – Reuters: ROCH.PA – Bloomberg: RCF FP), the worldwide leader in outsourced omnichannel customer experience management, serves companies and administrations around the world, with customer care, technical support, customer acquisition (Core Services), as well as with online interpreting solutions, visa application management services, data analysis and debt collection programs (Specialized Services). In 2016, Teleperformance reported consolidated revenue of €3,649 million (US$4,050 million, based on €1 = $1.11).

The Group operates 163,000 computerized workstations, with 217,000 employees across 340 contact centers in 74 countries and serving 160 markets. It manages programs in 265 languages and dialects on behalf of major international companies operating in a wide variety of industries.

Teleperformance shares are traded on the Euronext Paris market, Compartment A, and are eligible for the deferred settlement service. They are included in the following indices: CAC Large 60, CAC Next 20, CAC Support Services, STOXX 600 and SBF 120. They also have been included in the Euronext Vigeo Eurozone 120 index since December 2015, with regard to the Group’s performance in corporate responsibility.

For more information: www.teleperformance.com
Follow us: Twitter @teleperformance


Contacts

TELEPERFORMANCE
PRESS RELATIONS
MARK PFEIFFER
Phone: + 1 801-257-5811
mark.pfeiffer@teleperformance.com
or
INVESTOR RELATIONS
QUY NGUYEN-NGOC
SVETLANA SAVIN
Phone: +33 1 53 83 59 87/59 15
investor@teleperformance.com